Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
BSE Momentum Index
BSE Momentum Index Performance
Day's Range
Low
₹2,127.82
High
₹2,154.14
52 Week Range
Low
₹1,894.58
High
₹2,323.97
| Previous Close | ₹2,152.40 |
|---|---|
| Day's Range | ₹2,127.82 - ₹2,154.14 |
| Open | ₹2,136.37 |
| 52 Week Range | ₹1,894.58 - ₹2,323.97 |
| Volume | 1,49,93,842 |
BSE Momentum Index Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Bharat Electronics Ltd. | 419.80 |  12.45 (3.06%) |
Capital Goods |
| State Bank Of India | 1026.00 | 10.50 (1.03%) |
Bank |
| Max Financial Services Ltd. | 1631.50 | 19.75 (1.23%) |
Finance |
| Hindalco Industries Ltd. | 1009.00 | 26.60 (2.71%) |
Non - Ferrous Metals |
| The Federal Bank Ltd. | 322.50 | 1.85 (0.58%) |
Bank |
| Tata Steel Ltd. | 199.00 | 3.00 (1.53%) |
Iron & Steel |
| Ashok Leyland Ltd. | 159.50 | 1.00 (0.63%) |
Automobile & Ancillaries |
| Bharat Petroleum Corporation Ltd. | 317.95 | 6.15 (1.97%) |
Crude Oil |
| Eicher Motors Ltd. | 7509.00 |  -48.50 (-0.64%) |
Automobile & Ancillaries |
| Shriram Finance Ltd. | 1007.05 | 1.35 (0.13%) |
Finance |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 24085.7 | 26373.20 | 22182.55 |
| Nifty IT | 28809.55 | 40301.40 | 27078.00 |
| Nifty Next 50 | 72258.5 | 73098.95 | 59896.10 |
| NIFTY50 USD Index | 8832.4 | 10443.40 | 8132.40 |
| Nifty Bank | 57585.05 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 62123.35 | 62907.50 | 52032.85 |
| Nifty 500 | 23109.7 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 17659.65 | 17859.10 | 14804.55 |
| Nifty 100 | 25141.8 | 26975.15 | 22720.45 |
| Nifty FMCG | 49556.05 | 58485.05 | 45334.15 |
Latest News
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single‐Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. According to IQVIA® sales data for the 12‐month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market achieved annual sales of approximately $19.0 million. The company has attached media release.
3The above information is a part of company’s filings submitted to BSE.
Aditya Birla Capital informs about outcome of EGM
Aditya Birla Capital has informed regarding proceedings of Extra Ordinary General Meeting held on 12 June 2026. Further, the Company has submitted the exchange a copy of Scrutinizers Report along with Voting Results.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Aditya Birla Capital informs about allotment of equity shares
Glenmark Pharmaceuticals informs about investor presentation
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of SPBSMOIP index is ₹2152.4 as of 2026-06-17.
The total volume of SPBSMOIP index is 14993842.00 as of 2026-06-17.
The percentage change in value of SPBSMOIP index is 1.07% as of 2026-06-17.
The absolute increase in SPBSMOIP index value since the previous trading day is ₹22.76 as of 2026-06-17.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
